Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label study of an anti-IL-17A monoclonal antibody injection in Chinese adults with moderate-to-severe plaque psoriasis
CTR20240689Phase 3Active
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of amdokitug in plaque psoriasis, sponsored by 3S Guojian Pharmaceutical. Started Apr 2024; status: active.
02
Drugs
amdokitug
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on CTR20240689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240689.